Opinion statement
Chemotherapy (CT)-induced cardiotoxicity remains an unresolved problem that strongly affects the quality of life and overall survival of cancer patients. The most typical form of cardiotoxicity, a dilated cardiomyopathy (CMP), usually becomes manifest late in the course of the disease and is classically considered to be refractory to therapy. Preventing cardiotoxicity remains the most important strategy, and several measures have been proposed, including cardiac function monitoring, limitation of CT dose, use of anthracycline analogues and cardioprotectants, and early detection of cardiotoxicity by biomarkers. The response to modern heart failure therapy of CT-induced CMP has never been evaluated in clinical trials, and no definite guidelines have been adopted. Although it is likely that medications used for other forms of CMP, particularly angiotensin-converting enzyme inhibitors and β-blockers, may be highly effective, there is still some unjustified concern regarding their use in cancer patients.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References and Recommended Reading
Pai VB, Nahata MC: Cardiotoxicity of chemotherapeutic agents. Incidence, treatment and prevention. Drug Saf 2000, 22:263–302.
Yeh ETH, Tong AT, Lenihan DJ, et al.: Cardiovascular complications of cancer therapy. Diagnosis, pathogenesis and management. Circulation 2004, 109:3122–3131.
Barry E, Alvarez JA, Scully RE, et al.: Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. Expert Opin Pharmacother 2007, 8:1039–1058.
Jones RL, Ewer MS: Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs. Expert Rev Anticancer Ther 2006, 6:1229–1249.
Suter TM, Ewer MS: Trastuzumab-associated cardiotoxicity. In Cancer and the Heart. Edited by Ewer MS, Yeh ETH. Hamilton, ON: BC Decker Inc; 2006:67–64.
Youssef G, Links M: The prevention and management of cardiovascular complications of chemotherapy in patients with cancer. Am J Cardiovasc Drugs 2005, 5:233–243.
Wouters KA, Kremer LC, Miller TL, et al.: Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br J Haematol 2005, 131:561–578.
Silber JH, Cnaan A, Clark BJ, et al.: Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J Clin Oncol 2004, 22:820–828.
Healey Bird BRJ, Swain SM: Cardiac toxicity in breast cancer survivors: review of potential cardiac problems. Clin Cancer Res 2008, 14:14–24.
Libby P, Bonow RO, Mann DL, Zipes DP: The cancer patient and cardiovascular disease. In Heart Disease: A Textbook of Cardiovascular Medicine. Edited by Braunwald E. Philadelphia: Saunders Elsevier; 2008:2105–2117.
Felker GM, Thompson RE, Hare JM, et al.: Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000, 342:1077–1084.
Adams KF, Dunlap SH, Sueta CA, et al.: Relation between gender, etiology and survival in patients with symptomatic heart failure. J Am Coll Cardiol 1996, 28:1781–1788.
Cheitlin MD, Armstrong WF, Aurigemma GP, et al.: ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). Circulation 2003, 108:1146–1162.
Steinherz LJ, Graham T, Hurwitz R, et al.: Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Children Cancer Study Group. Pediatrics 1992, 89:942–949.
Meinardi MT, Van der Graaf WTA, Van Veldhuisen DJ, et al.: Detection of anthracycline-induced cardiotoxicity. Cancer Treat Rev 1999, 25:237–247.
Nielsen D, Jensen JB, Dombernowsky P, et al.: Epirubicin cardiotoxicity: a study of 135 patients with advanced breast cancer. J Clin Oncol 1990, 8:1806–1810.
Sabel MS, Levine EG, Hurd T, et al.: Is MUGA scan necessary in patients with low-risk breast cancer before doxorubicin-based adjuvant therapy? Am J Clin Oncol 2001, 24:425–428.
Jensen BV, Skovsgaard T, Nielsen SL: Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol 2002, 13:699–709.
Bristow MR, Mason JW, Billingham ME, et al.: Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy and cardiac catheterization. Ann Intern Med 1978, 88:168–175.
Telli ML, Hunt SA, Carlson RW, et al.: Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol 2007, 25:3525–3533.
Ewer MS, Henderson C, Martin FJ: Reduction in doxorubicin cardiotoxicity by the use of liposomal formulations of doxorubicin. In Cancer and the Heart. Edited by Ewer MS, Yeh ETH. Hamilton, ON: BC Decker Inc; 2006:67–64.
Spallarossa P, Garibaldi S, Altieri P, et al.: Carvedilol prevents doxorubicin-induced free radicals release and apoptosis in cardiomyocytes in vitro. J Mol Cell Cardiol 2004, 37:837–846.
Kalay N, Basar E, Ozdogru I, et al.: Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 2006, 48:2258–2262.
Panteghini M: Role and importance of biochemical markers in clinical cardiology. Eur Heart J 2004, 25:1187–1196.
Jensen JK, Atar D, Mickley H: Mechanism of troponin elevations in patients with acute ischemic stroke. Am J Cardiol 2007, 15:867–870.
Adamcova M, Sterba M, Simunek T, et al.: Troponin as a marker of myocardiac damage in drug-induced cardiotoxicity. Expert Opin Drug Saf 2005, 4:457–472.
Sparano JA, Brown DL, Wolff AC: Predicting cancer therapy-induced cardiotoxicity. The role of troponins and other markers. Drug Saf 2002, 25:301–311.
Cardinale D, Sandri MT, Martinoni A, et al.: Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol 2000, 36:517–522.
Cardinale D, Sandri MT, Martinoni A, et al.: Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol 2002, 13:710–715.
Cardinale D, Sandri MT, Colombo A, et al.: Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004, 109:2749–2754.
Lopez-Sendon J, Swedberg K, McMurray J, et al.: Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The task force on ACE-inhibitors of the European Society of Cardiology. Eur Heart J 2004, 25:1454–1470.
Jensen BV, Nielsen SL, Skovsgaard T: Treatment with angiotensin-converting-enzyme inhibitor for epirubicin-induced dilated cardiomyopathy. Lancet 1996, 347:297–299.
Okumura K, Jin D, Takai S, Miyazaki M: Beneficial effects of angiotensin-converting enzyme inhibition in adriamycininduced cardiomyopathy in hamsters. Jpn J Pharmacol 2002, 88:183–188.
Tokudome T, Mizushige K, Noma T, et al.: Prevention of doxorubicin (adriamycin)-induced cardiomyopathy by simultaneous administration of angiotensin-converting enzyme inhibitor assessed by acoustic densitometry. J Cardiovasc Pharmacol 2000, 36:361–368.
Vaynblat M, Shah HR, Bhaskaran D, et al.: Simultaneous angiotensin converting enzyme inhibition moderates ventricular dysfunction caused by doxorubicin. Eur J Heart Fail 2002, 4:583–586.
Sacco G, Bigioni M, Evangelista S, et al.: Cardioprotective effects of zofenopril, a new angiotensin-converting enzyme inhibitor, on doxorubicin-induced cardiotoxicity in the rat. Eur J Pharmacol 2001, 414:71–78.
Abd El-Aziz MA, Othman AI, Amer M, et al.: Potential protective role of angiotensin-converting enzyme inhibitors captopril and enalapril against adriamycin-induced acute cardiac and hepatic toxicity in rats. J Appl Toxicol 2001, 21:469–473.
Maeda A, Honda M, Kuramochi T, et al.: An angiotensin-converting enzyme inhibitor protects against doxorubicin-induced impairment of calcium handling in neonatal rat cardiac myocytes. Clin Exp Pharmacol Physiol 1997, 24:720–726.
Cardinale D, Colombo A, Sandri MT, et al.: Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006, 114:2474–2481.
Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA: A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973, 32:302–314.
Cohen M, Kronzon I, Lebowitz A: Reversible doxorubic-ininduced congestive heart failure. Arch Intern Med 1982, 142:1570–1571.
Haq MM, Legha SS, Choksi J, et al.: Doxorubicin-induced congestive heart failure in adults. Cancer 1985, 56:1361–1365.
Saini J, Rich MW, Lyss AP: Reversibility of severe left ventricular dysfunction due to doxorubicin cardiotoxicity. Report of three cases. Ann Intern Med 1987, 106:814–816.
Tallaj JA, Franco V, Rayburn BK, et al.: Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure. J Heart Lung Transplant 2005, 24:2196–2201.
Noori A, Lindenfeld J, Wolfel E, et al.: Beta-blockade in adriamycin-induced cardiomyopathy. J Card Fail 2000, 6:115–119.
Mukai Y, Yoshida T, Nakaike R, et al.: Five cases of anthracycline-induced cardiomyopathy effectively treated with carvedilol. Intern Med 2004, 43:1087–1088.
Fazio S, Calmieri EA, Ferravate B, et al.: Doxorubic-ininduced cardiomyopathy treated with carvedilol. Clin Cardiol 1998, 21:777–779.
Tabet JY, Meurin P, Ben Driss A, et al.: Beta-blockade intolerance in antracycline-induced cardiomyopathy. Int J Cardiol 2006, 106:132–134.
Lenihan DJ: Diagnosis and management of heart failure in the cancer patient. In Cancer and the Heart. Edited by Ewer MS, Yeh ETH. Hamilton, ON: BC Decker Inc; 2006:67–64.
Ewer MS, Vooletich MT, Durand JB, et al.: Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 2005, 23:7820–7826.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cardinale, D., Colombo, A. & Cipolla, C.M. Prevention and treatment of cardiomyopathy and heart failure in patients receiving Cancer Chemotherapy. Curr Treat Options Cardio Med 10, 486–495 (2008). https://doi.org/10.1007/s11936-008-0041-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11936-008-0041-x